Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

By J. D. de Bono, H. Scher, R. Montgomery, C. Parker, M. Miller, H. Tissing, G. Doyle, L. Terstappen, K. Pienta, D. Raghavan. Clinical Cancer Research, 2008

1,983 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/290835d1a01a043c8e46dbceb5ee7c2b46918153

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. L. Terstappen
2. G. Doyle
3. M. Miller
4. R. DePinho

In Oncology

1. G. Doyle
2. L. Terstappen
3. M. Miller
4. J. D. de Bono
5. R. DePinho
6. Jing Yang
7. J. Tsai

In Pulmonary and Respiratory Medicine

1. Celestia S. Higano
2. M. Hallek
3. C. Sawyers

Citations in the corpus

• Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer (2009, methodology): “Ideally, these modalities would be noninvasive, be independent of treatment, and provide quantitative real-time analysis of tumor activity in a variety of carcinomas.”
• Genetics and biology of prostate cancer (2018, background): “Baseline CTC count (Danila et al. 2007, 2011; de Bono et al. 2008; Scher et al. 2009; Goldkorn et al. 2014; Scher et al. 2015) and changes in posttreatment CTC count (Olmos et al. 2009; Scher et al. 2009; Goldkorn et al. 2014) were found to be prognostic factors for overall survival in prostate…”
• Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. (2016, background): “Although multiple platforms are under development,(22) CellSearch (Janssen Diagnostics, Raritan, NJ), which reports the number of cells captured from whole blood with an EpCAM-positive immunomagnetic ferrofluid, is the only US Food and Drug Administration–cleared CTC assay at the present time.(22) B”
• Molecular profiling for precision cancer therapies (2020, background): “, CTC dynamics in prostate and breast cancer patients treated with chemotherapy) [61, 62], early detection of resistance mechanisms [63, 64], assessment of tumor burden (e.”
• Circulating tumor cells: approaches to isolation and characterization (2011, background): “As with breast cancer, a correlation between pretreatment CTC numbers and clinical prognosis has been reported for patients with colorectal (Cohen et al., 2006) and prostate cancers (Danila et al., 2007; de Bono et al., 2008; Okegawa et al., 2009).”
• Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments (2022, methodology): “The CellSearch system has been prominent in establishing a correlation between CTC cell counts and predicting patient survival in PCa [15].”